Data science to understand and fight cancer

@machinelearnbot

For higher resolution, interactive Tableau charts, read original article. In this version, only static screenshots are displayed. It does not give justice to Tableau. Coming up with a topic for today's blog post was tough. My last blog about Wine got attention from wine entrepreneurs who had local wineries and collected sales data.


Scientists Hate the NIH's New Rules for Experimenting on Humans

WIRED

She's probably mostly kidding when she tells the origin story this way, but Kathy Hudson--until last year the deputy director for science, outreach, and policy at the National Institutes of Health--says that a massive update to the NIH's rules for funding science started with humiliation. A pal who ran approvals at the Food and Drug Administration, Hudson says, "used to walk around and talk about how NIH funded small, crappy trials, and they would say it at big gatherings." This was Washington, in front of congresspeople--or at conferences full of leading researchers. "I would get so pissed off," Hudson says.


How Artificial Intelligence is Transforming Clinical Trial Recruitment

#artificialintelligence

The medical world is shifting underneath our feet. To keep up with the rising demands of empowered patients, physicians and pharma businesses regularly test innovative treatments and medicines during rigorous clinical trials. But one misguided move can trigger a domino effect, such as when the wrong patients are selected for a clinical trial. Today's infographic comes to us from Publicis Health, and it highlights why the current model of clinical trial recruitment urgently needs to change. Clinical trials help to determine if a new treatment, drug, or device is safe for the larger patient population.


Alzheimer's disease: The right drug, the right time

Science

Alzheimer's disease (AD) is an age-associated neurodegenerative disease that is reaching epidemic proportions as a result of the aging of the world's population. Impressive gains in our understanding of AD pathogenesis have not yet translated into disease-modifying therapies that benefit patients. Is this because the knowledge that guides target identification and, hence, therapeutics, is insufficient? Are current clinical trial designs not optimal? Or are other factors contributing?


How the IoT is changing clinical trials

@machinelearnbot

The Internet of Things is influencing nearly every aspect of our lives. Everything from our home appliances to traffic signals to our workplaces is connected to the Internet, and the network only continues to expand. It seems that no industry is left untouched by the IoT, and that includes healthcare. In fact, some have even argued that healthcare is perhaps the best place for IoT applications. Here, connected devices have the potential to increase access to providers, improve the quality of care thanks to more accurate patient information, and allow patients to take more control over their overall health.